The helium trimer with soft-core potentials

The helium trimer is studied using two- and three-body soft-core potentials. Realistic helium-helium potentials present an extremely strong short-range repulsion and support a single, very shallow, bound state. The description of systems with more than two helium atoms is difficult due to the very large cancellation between kinetic and potential energy. We analyze the possibility of describing the three helium system in the ultracold regime using a gaussian representation of a widely used realistic potential, the LM2M2 interaction. However, in order to describe correctly the trimer ground state a three-body force has to be added to the gaussian interaction. With this potential model the two bound states of the trimer and the low energy scattering helium-dimer phase shifts obtained with the LM2M2 potential are well reproduced.Comment: 15 pages, 3 figures, submitted to Few-Body System

The potential utility of B cell-directed biologic therapy in autoimmune diseases

Increasing awareness of the importance of aberrant B cell regulation in autoimmunity has driven the clinical development of novel B cell-directed biologic therapies with the potential to treat a range of autoimmune disorders. The first of these drugs—rituximab, a chimeric monoclonal antibody against the B cell-specific surface marker CD20—was recently approved for treating rheumatoid arthritis in patients with an inadequate response to other biologic therapies. The aim of this review is to discuss the potential use of rituximab in the management of other autoimmune disorders. Results from early phase clinical trials indicate that rituximab may provide clinical benefit in systemic lupus erythematosus, Sjögren’s syndrome, vasculitis, and thrombocytopenic purpura. Numerous case reports and several small pilot studies have also been published reporting the use of rituximab in conditions such as myositis, antiphospholipid syndrome, Still’s disease, and multiple sclerosis. In general, the results from these preliminary studies encourage further testing of rituximab therapy in formalized clinical trials. Based on results published to date, it is concluded that rituximab, together with other B cell-directed therapies currently under clinical development, is likely to provide an important new treatment option for a number of these difficult-to-treat autoimmune disorders

Coherent reflection of he atom beams from rough surfaces at grazing incidence

Contains fulltext : 99077.pdf (preprint version ) (Open Access

Quantum reflection of he-2 several nanometers above a grating surface

Contains fulltext : 98946.pdf (publisher's version ) (Closed access